Preclinical drug formulation and analysis group

We are a very multidisciplinary research group of life sciences and medical technology that comprises pharmacists, engineers, chemists, physicists, biologists, and nanotechnologists with a wide variety of expertise in the fields of pharmaceutical sciences, biomedical engineering, materials science, and analytical chemistry. We focus on pre-clinical screening and development of new and advanced technology for drug delivery (e.g., nanocarriers and nanocrystallization), bioanalysis (e.g., biochemical microreactors and micro total analysis systems), and novel and more sensitive, label free optical techniques (e.g., Raman and CARS), and selective and faster methods for the analysis of different compounds (e.g., miniaturized devices). Unit's principal investigators are listed below.

ftdk drp Santos Pre­clin­ical drug for­mu­la­tion and ana­lysis kaavio

Focusing on the development of nanoparticles/nanomedicines for biomedical and healthcare applications. We make the bridge between biomedical engineering and pharmaceutical. We use biodegradable and biocompatible nanoporous silicon nanomaterials and polymeric nanoparticles, together with the microfluidic technology for production of advance nanomedicines for simultaneous controlled drug delivery, diagnostic and treatment of cancer, diabetes, and cardiovascular diseases, and for further translation of these nanotechnologies into the clinic.

Nanomedicine: Making Drugs more Precise

Developing novel biomaterials for pharmaceutical technology applications, and controlled/targeted nanotechnology approaches for drug delivery systems. We focus on the drug delivery via the oral, cutaneous and pulmonary routes, as well as parenteral (targeted, precisely dosed drug delivery) administration routes of nanopharmaceutics.

Focusing on the implementation of microchip-based technology for mass spectrometry-based bioanalysis and drug metabolism research. We develop new in vitro technology for studying the molecular level interactions between the environmental and household chemicals with clinically used drugs. We also conduct cautions drug design and development with the aim of reducing the amount and hazards of pharmaceutical residues in the environment is another important goal of the group’s research.

Helsinki Challenge Pitch Night Jan 28 & 29, 2015: Generation Green

Utilization of nanocrystallization techniques for improved solubility and higher bioavailability of poorly soluble materials. Research focus is on production of drug nanocrystals, their thorough physicochemical characterization, especially developing reliable dissolution and solubility profile testing methods, and formulation studies based on drug nanocrystals. We have the capability for both bottom-up as well as top-down methods for nanocrystallization; different production scales are available starting from batch sizes with tens of milligrams for screening purposes. We have been concentrating especially for multifunctional excipient studies for drug nanocrystals and new materials like nanocellulose, dendrimers and hydrophobins have been screened.

Well-versed in a variety of fields, such as controlled drug delivery, nanomedicine and microfluidics. Primarily, we are interested in engineering optimal drug delivery systems by microfluidic techniques. For example, by exploiting superfast time intervals between sequential nanoprecipitation processes, we have produced structured nanocomposites. These nanocomposites harness the inherent ultrahigh drug loading degree and enhanced payload dissolution kinetics of drug nanocrystals and the controlled drug release from polymer-based nanoparticles. Beyond the engineering of optimal nanocomposites, we focus on their biomedical applications, such as cancer targeting drug delivery and spinal cord injury therapy.